A recent meta-analysis from the Antiplatelet Trialists' Collaboration recommended that antilatelet treatment either alone or, for greater effect, in addition to other proved forms of thromboprophylaxis should be considered for patients at high risk of thromboembolism. This paper argues that the current (1) A few weeks of antiplatelet treatment roughly halved the risk both of deep vein thrombosis and of pulmonary embolism in a wide range of surgical patients (and the limited evidence in immobilised medical patients was also encouraging).
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(2) The absolute benefits seemed to be greater for those at higher risk-for example, those undergoing orthopaedic surgery.
(3) Antiplatelet treatment can be conveniently continued after discharge from hospital (in contrast with many other forms of prophylaxis) for as long as the risk ofthromboembolism remains substantial.
(4) Antiplatelet treatment alone or, for greater effect, in addition to other proved forms of prophylaxis should be considered for patients at high risk of thromboembolism.
Our aim is to encourage constructive debate about these conclusions, taking into account the limitations of a meta-analysis. It is well established that a large number of issues concerning meta-analysis relate to difficulties in the evaluation of clinical trials particularly factors such as limited information on individual studies, "combinability," biases, confounders and effect modifiers, heterogeneity of treatment effects, effect of size (small versus large studies), and the differential qualities of studies.' This recent metaanalysis has also raised other important issues which need to be resolved, including the consideration of a risk-benefit assessment, the interpretation of the results, and the general recommendations which have been made. We consider that the conclusions of the antiplatelet trialists cannot be justified after taking into account many of these factors that can affect the results of a meta-analysis. The Antiplatelet Trialists' Collaboration states that the absolute benefits seem to be greater for those at higher risk-for example, those undergoing orthopaedic surgery. This is inaccurate as the benefit was least for those undergoing traumatic orthopaedic surgery. It was also stated that antiplatelet thromboprophylaxis can be conveniently continued after discharge. No trial, however, has yet been published to support this statement with respect to either efficacy or safety.
Conclusions ofthe meta-analysis
These conclusions have ignored the proved beneficial effects of other methods of prophylaxis. It was stated that antiplatelet treatment should be used either alone or in addition to other forms of thromboprophylaxis. The In many of the trials in this latest meta-analysis the authors state that they were unable to make an assessment of the safety and complications of bleeding as such data were not recorded. This information is not optional data for completeness but is absolutely essential to determine the risk-benefit ratios, which must always be clearly defined before any general recommendations are made. This is of particular importance when we consider the recommendation to use combined treatment, which is known to be associated with an increased risk ofbleeding and hence may be unsafe. This is exemplified by the results of the studies that were quoted which compared aspirin and heparin with aspirin alone."'7 These studies did assess safety and bleeding and showed that combined treatment was associated with increased bleeding. In 534 patients, six (1-1%) major bleeds occurred in the combined treatment group compared with one (0 2%) of the 535 patients in the antiplatelet group, and the respective figures for reoperation, wound haematoma, and wound infection were 43 (8*1%) and 17 (3 2% ). This point is further supported by the results of our recent multicentre trial of thromboprophylaxis in 3809 patients undergoing major abdominal surgery. We reported that the 292 patients who took antiplatelet treatment in combination with heparin treatment had an increased risk of bleeding (relative risk 1 41, 95% confidence interval 1-05 to 1 88, P=0-03)." Increased bleeding has also been reported with combined treatment in orthopaedic surgery. '9 Conclusion ofthe debate There is no doubt that meta-analysis is a powerful statistical tool. It can, however, only ever be as good as the constituent clinical trials which are used for analysis. If no attempt is made to assess the quality of trials published and then exclude those that fall short of the predefined standards, meta-analysis will surely generate data that are misleading at best and overtly dangerous at worst. What can really be recommended from this meta-analysis? Which of the 10 antiplatelet drugs should be used in which of the innumerable combinations and at what dose? One of the most effective antiplatelet regimens in elective orthopaedic surgery was aspirin 3900 mg a day.20 This is the equivalent of three proprietary aspirin tablets four times a day, and it is difficult to believe anyone would recommend this regimen to an elderly woman about to have her hip replaced. Not surprisingly, this was associated with an 8% incidence of major gastrointestinal bleeding and a 24% incidence of tinnitus, which necessitated a reduction in the dose.
In a study of any pharmacological intervention there are always two sides to the equation. In this case the aim is the prevention of thromboembolic disease, and the risk is always that there will be increased bleeding. All clinical decisions entail some degree of risk-benefit analysis, and in orthopaedic surgery the need for effective prevention of deep vein thrombosis with minimal risk of bleeding is essential. Any clinical trial that does not disclose data regarding bleeding compli-BMJ VOLUME 309 cations must surely be discarded. Equally, an overview which clearly states that it has used data from studies in which comparison of bleeding was not possible and then makes recommendations for clinical practice must be viewed with great caution.
In conclusion, we believe the following points should be made.
Firstly, it is time to define the minimum criteria before including studies in a meta-analysis.
Secondly, at present there is insufficient evidence to justify use of antiplatelet agents for thromboprophylaxis.
Thirdly, this meta-analysis has resulted in regressive recommendations which may lead to consideration of treatment with lesser efficacy and safety than currently available regimens with low dose heparins.
Fourthly, in view of these serious reservations we suggest that the recommendations of the antiplatelet trialists are not put into practice.
Finally, we agree that there is a need for well designed, large, blinded trials to compare antiplatelet and anticoagulant thromboprophylaxis. APT Antiplatelet therapy for thromboprophylaxis: the need for careful consideration ofthe evidence from randomised trials R Collins, C Baigent, P Sandercock, R Peto for the Antiplatelet Trialists' Collaboration Venous thrombosis and pulmonary embolism remain an important cause of morbidity and mortality both in surgical patients and in immobilised medical patients."-5 Various thromboprophylactic treatments have, therefore, been devised to prevent or limit thromboembolism. Our previous systematic overview (or meta-analysis) of randomised trials of perioperative subcutaneous heparin found that among surgical patients such treatment can roughly halve the risk not only of deep venous thrombosis but, more importantly, of pulmonary embolism6 (see fig 1) . Subcutaneous heparin is now widely recommended for surgical or medical patients at high risk of venous occlusion. "5 Prospectively defined methods for overviews (metaanalyses)
The recent Antiplatelet Trialists' Collaboration overview of the thromboprophylactic effects of antiplatelet therapy used prospectively determined criteria for trial inclusion and treatment comparisons that were similar to those of the previous heparin overview." The aim was to include all unconfounded properly randomised trials of antiplatelet versus no antiplatelet therapy (or of one antiplatelet regimen versus another) that could have been available for review by March 1990 in which deep venous thrombosis was systematically and unbiasedly monitored. (Parts I and III of the previous overview report give a fuller description of the methods used.'7 The appropriateness of using "assumption free" statistical methods rather than the "random effects" model when combining trial results, as when combining results from different centres in a multicentre trial, has been discussed in detail previously.9 10) Such randomised trials were to be included whether or not the treatment comparison was "blinded" by placebo control. This was also the case in the heparin overview, where exclusion of informative "open" trials (in particular, the important open international multicentre trial coordinated by Professor V V Kakkar") would have been equally inappropriate. Analyses confined to placebo controlled studies, which may be less subject to treatment dependent biases in the assessment of subjective outcome measures, were, however, also considered separately (but, as was shown,' these would not materially alter the conclusions: see below).
When the data collected did not include information about the prospectively defined outcomes of interest among all patients initially randomly assigned, extra details were sought from the principal investigators.17 It was often possible to obtain such information, but when it was not the available data were to be included in the overview-unless the numbers missing were so extensive that the comparison could no longer be considered properly randomised. For example, in the study by Soreff et al results of venographic follow up were available for only 14 of 25 patients allocated placebo and for 21 of 26 allocated aspirin.'2 So, although the pulmonary emboli data were to be included from this study, the venographically identi-
